XenoSTART

We’re thrilled to share that XenoSTART will present three posters at #AACR 2025, showcasing our latest innovations in preclinical oncology research. Our presentations will cover cutting-edge advancements in patient-derived xenograft (#PDX) models, novel therapeutic evaluations, and translational research that bridges the gap between preclinical data and clinical outcomes. XenoSTART's unique direct PDX-to-patient approach, leveraging directly sourced clinical samples from The START Center for Cancer Research clinical network, ensures unparalleled clinical relevance and predictive accuracy for oncology drug development. Let's discuss how our models and insights can support your preclinical and translational research goals. Schedule a meeting with us at AACR: https://lnkd.in/eF_WQvCD #Preclinical #OncologyResearch Alyssa Simonson, Johnnie Flores

During Colorectal Cancer Awareness Month, we’re proud to spotlight our collection of over 300 unique colorectal cancer (CRC) patient-derived xenograft (PDX) models. These models are not only difficult to grow but also directly sourced from real-world clinical samples within our START clinical network—ensuring unmatched clinical relevance. Our direct patient-to-PDX pipeline bridges the translational gap, offering researchers a robust platform to evaluate new therapies with a higher likelihood of clinical success. Whether you're exploring standard chemotherapies, novel targeted agents, or immunotherapies, our CRC models provide the predictive accuracy needed to advance your drug development programs. Explore our catalog of clinically relevant CRC models: https://lnkd.in/eQGjXhkf ? #preclinical #colorectalcancer #CRC

The divide between preclinical research and clinical application has long been a challenge in oncology drug development. Too often, promising therapies falter because preclinical models fail to capture the complexities of real-world patient responses. XenoSTART is eliminating that gap. With the world’s largest collection of clinically sourced PDX models, continuously obtained from our global network of early-phase clinical trial sites, we bring real-world patient data into the preclinical space. Our models are not just highly characterized—they are deeply annotated with patient treatment histories, molecular profiling, and in vivo drug responses. This direct connection between patient-derived insights and translational research accelerates drug discovery, optimizes clinical trial design, and ensures greater relevance in drug development. This is more than preclinical research. It’s a seamless, fully integrated approach to oncology innovation. Let’s talk about how XenoSTART can support your program with a true bench-to-bedside model that transforms the way new therapies reach patients. Don’t wait. Level up your translational research with XenoSTART. Schedule a meeting with us: https://lnkd.in/da9cXFWX #preclinical #drugdevelopment #oncologyresearch

Finding the right patient-derived xenograft (PDX) model can make or break a preclinical oncology program. At XenoSTART, we offer the industry’s most expansive catalog, continuously updated with newly sourced tumor samples from real patients across The START Center for Cancer Research's global clinical trial network. https://lnkd.in/eRciHcYn Every model in our catalog is deeply annotated with comprehensive patient treatment histories, molecular profiles, and in vivo drug response data—giving sponsors a real-world window into tumor biology. Whether you’re targeting a well-known pathway or a rare mutation with limited preclinical models available, our catalog delivers the diversity and specificity needed to drive translational success. Explore our catalog today and discover the next model for your research. https://lnkd.in/eRciHcYn #pdxmodels #oncologyresearch #cancer #preclinical

Small cell lung cancer (SCLC) remains a devastating disease with limited treatment options, making preclinical research critical to advancing new therapies. XenoSTART has developed an extensive panel of 18 patient-derived xenograft (XPDX) models, many of which originated from our Phase 1 partners at START San Antonio and START Madrid. These clinically sourced models represent both treatment-na?ve and relapsed disease states, offering a powerful platform for evaluating standard chemotherapies, antibody-drug conjugates (ADCs), and emerging targeted therapies. ? Findings from our research highlight that treatment-na?ve models showed greater sensitivity to chemotherapy, emphasizing the importance of early intervention. Temozolomide demonstrated significant tumor regression in both na?ve and pretreated models, reinforcing its role in SCLC treatment. ADCs such as trastuzumab deruxtecan (T-DXd), enfortumab vedotin (EV), and sacituzumab govitecan (SG) showed varied efficacy, providing valuable insights into potential new treatment avenues. Genetic profiling identified key mutations and gene fusions in KRAS, RB1, TP53, and other oncogenic drivers, opening doors for targeted drug development. By leveraging XPDX models sourced directly from clinical trials, XenoSTART is bridging the gap between preclinical research and clinical application, accelerating the development of new treatments for SCLC. Let us show you how. Schedule a meeting today:?https://lnkd.in/da9cXFWX #preclinical #oncologyresearch #pdxmodels

Preclinical oncology research demands models that truly reflect patient biology. That’s why XenoSTART offers the industry’s largest and most clinically relevant PDX model catalog, sourced directly from patients in active clinical trials. With 2,800+ patient-derived xenograft (PDX) models, including lung, breast, bladder, and rare tumor types, our catalog provides deeply annotated models with full treatment histories and molecular data, allowing researchers to quickly identify the most clinically relevant model for their drug development needs. These models help optimize preclinical studies by mirroring real-world patient responses, making them a powerful tool in translational oncology research. Explore the searchable catalog and find the right PDX model for your research. https://lnkd.in/eRciHcYn #preclinical #PDX #drugdevelopment #cancerresearch #oncology

CDK4/6 inhibitor resistance remains a critical challenge in ER+ breast cancer, requiring new strategies to understand resistance mechanisms and develop effective therapies. At the SABCS Conference, XenoSTART presented a poster highlighting our expanding collection of 32 patient-derived xenograft (PDX) models from patients post-CDK4/6 inhibitor treatment. This research underscores XenoSTART’s unique translational platform, leveraging clinically sourced tissue, in vivo drug response benchmarking, and deep molecular profiling to provide a comprehensive view of resistance mechanisms. By integrating detailed patient treatment histories—including duration of therapy and time to progression (TTP)—we are helping to identify potential pathways of resistance and novel targets for drug development. Our findings reinforce that XenoSTART’s clinically relevant PDX models are a powerful tool for the development of next-generation therapies for CDK4/6i-resistant patients. We are committed to bridging preclinical research with clinical insights, ensuring that breast cancer drug development is informed by real-world patient data. Congratulations to lead author Delaney Rushing and co-authors from XenoSTART and our START Phase 1 clinics for their contributions to this important work! #preclinical #pdx #oncologyresearch #drugdevelopment

We’re excited to have Dr. Michael Wick, Ph.D., our Chief Scientific Officer, presenting at Tumor Models London tomorrow at 9:00 AM during the general session. His talk, "Signal vs. Noise: Using Clinically Relevant Preclinical Models to Advance Cancer Therapies," will highlight how precision science relies on high-quality, representative models to produce accurate results in preclinical testing. ? Many PDX suppliers prioritize quantity over quality; XenoSTART offers models representing the clinical status of patients who will be treated on early phase trials.?Our platform eliminates the "black box" nature of many models, addressing key questions like their origin, patient annotation history, and whether they represent a relevant patient population—all while ensuring they perform as advertised. ? Discover how the XenoSTART way is redefining preclinical research to advance cancer therapies: https://lnkd.in/ePKU4DSK ? #TumorModelsLondon #PreclinicalResearch #PDXModels

Our Chief Scientific Officer, Dr. Michael Wick, Ph.D., recently authored an article in Today's Clinical Lab titled,?“Capturing the Complexity of Real Cancer Cases with Patient-Derived Xenograft Models.” ? The article dives into how patient-derived xenograft (#PDX) models are reshaping cancer research by providing more accurate, clinically relevant data compared to traditional models. Dr. Wick explores the advantages of PDX models in replicating real patient treatment histories, their use in second- and third-line therapies, and their potential for advancing precision medicine. ? Are your PDX models delivering the depth of data and quality you need for your #preclinical research? Don’t settle for less when XenoSTART offers a best-in-class approach. ? Check out the full article here: https://lnkd.in/eSucBnCp

XenoSTART is proud to sponsor the Tumor Models London Conference, taking place December 4-5. This event is an incredible opportunity for the oncology research community to connect, share knowledge, and advance cancer research. ? At XenoSTART, we’re committed to supporting groundbreaking preclinical research. Our growing PDX inventory of 2,500+ models provides researchers with valuable tools to better understand and combat cancer. And best of all, our models are sourced directly from our patients across our Phase 1 clinics. ? Are you looking to enhance your preclinical studies? Let’s discuss how our models can support your R&D goals. Schedule a meeting: https://lnkd.in/eDrWxzRn ? #TumorModelsLondon #CancerResearch #PDXModels #PreclinicalResearch Lindsay Belcher, Ryan Carpentier, Alyssa Simonson, Dr. Michael Wick, Ph.D.